Search results
Biogen (BIIB) & Eisai's Leqembi sBLA Gets FDA Acceptance
Zacks via Yahoo Finance· 3 days agoFDA accepts Biogen's (BIIB) partner Eisai's sBLA for a maintenance intravenous dosing version of...
Class Action Filed Against Biogen Inc. (BIIB) - July 22, 2024 Deadline to Join – Contact The Gross...
Benzinga· 7 days agoThe Gross Law Firm issues the following notice to shareholders of Biogen Inc. BIIB. Shareholders who purchased shares of BIIB during the class period listed ...
...Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm - Charge Enterprises Inc...
Benzinga· 4 days agoBragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Biogen
BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class...
Morningstar· 3 days agoDo you, or did you, own shares of Biogen Inc. (NASDAQ: BIIB)? Did you lose money in your investment in Biogen Inc.
Biogen Inc. Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges BIIB Investors with Losses to...
Morningstar· 3 days agoThe law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District ...
Eli Lilly's Alzheimer's drug gets backing from FDA advisers
Morningstar· 3 days agoEli Lilly & Co.'s experimental Alzheimer's drug donanemab on Monday moved a step closer to U.S. regulatory approval as it won support from an independent panel of advisers to the Food and Drug ...
...s Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst -...
Benzinga· 2 days agoEli Lilly's donanemab for Alzheimer's disease garners positive FDA committee verdict, prompting analyst's bullish outlook amid comparisons to Biogen's Leqembi.
Eli Lilly’s Alzheimer’s drug to face safety, dosing scrutiny from FDA advisers
Market Watch· 6 days agoIn a briefing document prepared for the advisory committee, the FDA raised questions about a unique...